Compare Ishares Msci Italy ETF (EWI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Italy ETF vs Novo Nordisk A/S — how do they compare? Ishares Msci Italy ETF trades at $63.12, while Novo Nordisk A/S trades at $46.32 (market cap $207.85B). The key difference: Novo Nordisk A/S pays a 3.81% dividend while Ishares Msci Italy ETF pays none, and Ishares Msci Italy ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| EWI | NVO | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $63.98 |
52-Week Low | $50.31 | $35.29 |
Market Cap | — | $207.85B |
Enterprise Value | — | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWI trades at $63.18, up 0.02% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock recently hit a 52-week high, driven by positive European market sentiment and Italy's economic recovery narrative. A dividend of $1.17 is scheduled for June 2026, offering income potential.
Outlook is cautiously optimistic given strong technical momentum and favorable European equity flows, but risks include ECB policy shifts and energy price volatility. Investors should weigh technical overbought conditions against fundamental growth prospects in Italy's market.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
